Nutritionals Lead Consumer Health Sales Growth On Condition-Specific Claims
This article was originally published in The Tan Sheet
"There's been a change in the nutritional mindset, a change in the nutritional focus," says IRI executive Bob Sanders. Respiratory treatments led growth among OTC drug categories in 2015, pushed by recent switches and with allergy products accounting for 30% of the category's sales.
You may also be interested in...
FDA approval for Perrigo's ANDA for two loperamide products listed as tablets follows CBE label changes Johnson & Johnson and BionPharma made for their branded OTCs containing the ingredient in 2019.
US OTC Decisions In June: Third Tentative Approval For Omeprazole Delayed Release ANDA, More Esomeprazole PPI Final Approvals
FDA told P&L Development, as it had with Aurobindo Pharma and Hetero Drugs, that its ANDA for a generic of Prilosec OTC delayed release is tentatively approved because exclusivity has not expired for Perrigo's first-approved generic of the PPI.
Appropriations subcommittee notes the funding in summary of its draft budget bill. Language on FDA’s development of CBD regulatory framework will be included in panel’s report to be released 24 hours before full committee’s markup.